* Aclidinium bromide (Tudorza Pressair) is a new powdered, inhaled anticholinergic that has been approved for the treatment of chronic obstructive pulmonary disease. The drug is used daily to prevent or minimize bronchospasms.
* Aclidinium bromide can produce paradoxical bronchospasms and immediate hypersensitivity reactions (especially in those with a history of hypersensitivity to atropine or milk proteins). If either of these occurs, the drug should be discontinued.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.